Escitalopram and suicidality in adult depression and anxiety
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The escitalopram clinical trial database, consisting of all placebo-controlled and relapse prevention trials within major depressive disorder (MDD) and anxiety disorders, was analysed for specific adverse events indicative of suicidal behaviour (fatal suicide, non-fatal self-harm or suicidal thoughts) in relation to treatment. The number of events was low, with no fatal suicides in the first 2 weeks of treatment. There was one fatal suicide during the full treatment period on placebo (incidence 0.1%; rate 0.003), and none on escitalopram. None of these figures were significantly different between escitalopram (n=2277) and placebo (n=1814) patients. There was no indication that escitalopram provokes suicidal behaviour compared to placebo in either MDD or anxiety disorders. Based on efficacy ratings (Montgomery-Asberg Depression Rating Scale, item 10), escitalopram was more efficacious versus placebo in lowering suicidal thoughts from weeks 1 through 8 in the treatment of patients with MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881 · cited 1×
“Mood disorders are linked to an increased risk of suicide (Angst et al., 2002).”
BackgroundLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 2×
“…2002; Lepola et al., 2003; Ninan et al., 2003; Rapaport et al., 2004; Reines et al., 2004; Montgomery et al., 2003), panic disorder (Stahl et al., 2003), social anxiety disorder (Lader et al., 2004; Kasper et al., 2005) and generalized anxiety disorder (Goodman et al., 2003; Davidson et al., 2004).”
BackgroundEscitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Cited by
Suicidal risks among 2826 Sardinian major affective disorder patients
Tondo, L., Lepri, B., & Baldessarini, R. J. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01066.x · Cited by 177
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
Antidepressants and Suicide Risk: A Comprehensive Overview
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Giordano, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · Pharmaceuticals · doi:10.3390/ph3092861 · Cited by 53
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Metadata
- Authors
- Pedersen, A. G.
- Venue
- International Clinical Psychopharmacology
- Published
- 2005-05
- Volume
- 20
- Issue
- 3
- Pages
- 139-143
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2029526374
- Cited by
- 44
- References
- 3
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram and suicidality in adult depression and anxiety. https://app.cochat.ai/papers/10.1097/00004850-200505000-00003
- The paper
- Pedersen, A. G. (2005). Escitalopram and suicidality in adult depression and anxiety. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200505000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.